Financial Results (Amount in ₹ Lakhs)

Quarter Ended March 31, 2026 (Audited):

  • Revenue from operations: ₹202.49
  • Total Income: ₹205.03
  • Total Expenses: ₹1,542.76
  • Profit before tax: ₹22.28
  • Net profit: ₹17.86
  • EPS: ₹0.07

Year Ended March 31, 2026 (Audited):

  • Revenue from operations: ₹12,908.33
  • Total Income: ₹12,910.87
  • Total Expenses: ₹12,556.39
  • Profit before tax: ₹354.48
  • Tax expense: ₹91.29
  • Net profit: ₹263.19
  • EPS: ₹1.00

Comparative Figures (Year Ended March 31, 2025):

  • Revenue from operations: ₹12,491.71
  • Net profit: ₹97.40
  • EPS: ₹0.41

Segment-wise Performance (Year Ended March 31, 2026)

  • Chemicals Segment: Revenue ₹5,819.19 lakhs, Segment Result (₹512.35) lakhs
  • Steel Segment: Revenue ₹7,089.14 lakhs, Segment Result ₹866.83 lakhs
  • Total Segment Revenue: ₹12,908.33 lakhs
  • Total Segment Result: ₹354.48 lakhs

Capital Structure

  • Paid-up equity share capital: ₹2,628.92 lakhs (Face value ₹10 each)
  • Other equity (Reserves): ₹1,774.39 lakhs
  • Share warrant money received: ₹1,827.01 lakhs

Cash Flow Statement (Year Ended March 31, 2026)

  • Net cash from operating activities: (₹1,832.23) lakhs
  • Net cash from investing activities: (₹4.07) lakhs
  • Net cash from financing activities: ₹1,880.03 lakhs
  • Net increase in cash: ₹43.73 lakhs
  • Cash equivalents at year end: ₹86.30 lakhs

Fundraising Activities

  • The company received 25.00% of total consideration (₹18,93,31,031) for 5,80,32,500 convertible warrants at ₹13.05 per warrant in Board Meetings held on 9th September 2025 and 12th September 2025.
  • The company received 75.00% of total consideration (₹2,19,63,150) for 22,44,000 equity shares allotted pursuant to warrant conversion at ₹13.05 per share in Board Meeting held on 29th November 2025.

Related Party Transactions

Significant related party transactions during the period:

  • Loan taken from Dhara Chemicals: Opening balance ₹66.41 lakhs, Closing balance ₹66.41 lakhs
  • Commission paid to Dhara Chemicals: ₹373.17 lakhs
  • Commission paid to Dipan Pharma Chem: ₹727.18 lakhs
  • Transactions with CEDAC Medicorp: Net amount (₹1,662.94) lakhs

Compliance Declarations

  • No deviation/variation in utilization of funds raised through preferential issue
  • No outstanding defaults on loans and debt securities
  • Audit committee reviewed and Board of Directors approved the results on 2nd July 2026

Balance Sheet Highlights (as of 31st March 2026)

  • Total Assets: ₹20,562.94 lakhs
  • Current Assets: ₹15,408.99 lakhs (including Inventories ₹4,232.54 lakhs, Trade receivables ₹4,800.45 lakhs)
  • Total Liabilities: ₹20,562.94 lakhs
  • Current Liabilities: ₹13,322.60 lakhs